Navigation Links
CuraGen Presents Update on Clinical Development Program for,Belinostat

706-758-4315 (international) Passcode: 2474675 Webcast: Access to the live webcast and presentation are available at http://www.curagen.com

A replay of the conference call will be available starting at 11:30 a.m. Eastern time on Tuesday, June 12, 2007 through Sunday, August 12, 2007 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 2474675. An archive of the webcast will also be accessible at http://www.curagen.com.

Reprints of the poster presentations are available on CuraGen's website at www.curagen.com , or by emailing . info@curagen.com

About Belinostat

Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azacitidine, doxorubicin and Velcade(R) (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti- cancer agents.

Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for multiple myeloma, T- and B-cell lymphomas, AML, mesothelioma, liver, soft tissue sarcoma, colorectal, ovarian cancers, either alone or in combination with anti-cancer therapies. An oral formulation of beli
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:12/1/2008)... ROCKVILLE, Md., Dec. 1 ...rts publication in The Lancet , one of the world,...ials of its novel circadian regulator, experimenta... by Rajaratnam et al(1) is entitled "Melatonin ago...after sleep-time shift: two randomised controlled ...
(Date:12/1/2008)... St. Jude study shows the Prox1 gene is a two-way...thelial cells to be reprogrammed so that they lose...lial cells , , MEMPHIS, Tenn., Dec. 1 /PRNe...dren,s Research Hospital have discovered that a ce...ge its identity that it requires the constant expr...
(Date:12/1/2008)... ATLANTA, Dec. 1 GeoVax...a-based biotechnology company developing,human va...eficiency Virus) and,other infectious agents, ann...,Vaccine Trials will take place in twelve sites a...onducted in collaboration with The National Instit...
(Date:11/28/2008)... INDIANAPOLIS, Nov. 28 ...n its supplemental New Drug Application (sNDA) fro... Cymbalta(R) (duloxetine HCl),for the management ...cation in,the first half of 2009, adding data fro...osteoarthritis pain of the knee. , The deci...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 1UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 2UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 3UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 1NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 2NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 3NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 5Shape Shifting on Veterans Day 5756 1Shape Shifting on Veterans Day 5756 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 1More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 3More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 4
...LE, Calif., April 16, 2007 /PRNewswire-FirstCall/ ...anism of action of,its anti-cancer agent BZL101, w...r late stage breast cancer at the American,Associa...os Angeles,Convention Center in Los Angeles, CA, A...n will describe the pathway for,cancer cell apopto...
...agonist Demonstrates Clinical Activity, a Novel Me...other HCV Inhibitors-, NEW HAVEN, Conn., April 16,...uticals, Inc. today announced the presentation of,... one of,Achillion,s NS4A antagonists, ACH-806, for...n at the 42nd Annual Meeting of the,European Assoc...
Other Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4
(Date:12/2/2008)...stCall/ -- Genoptix, Inc. (Nasdaq: GXDX ), a spe...nced the Company,s participation at the RBC Capita...take place at the Westin New York Hotel at Times S...ccitelli, COO and executive vice president of Geno...conference on Wednesday, December 10, beginning at...
(Date:12/2/2008).../ -- LCA-Vision Inc. (Nasdaq:, LCAV ), a leading...r the,LasikPlus(R) brand, today announced that me...nt at RBC Capital Markets, 2008 Healthcare Confere...astern time. The conference is,being held at The... archived,webcast of the event will be available ...
(Date:12/2/2008)... -- In response to the commentary entitled "Cod Li...Infections, and the Vitamin D Deficiency Epidemic"...ement experts, Nordic Naturals announced today tha...promise to consumers and actually offer healthy om...itamin A. According to Karin Yien, MD, Nordic Natu...
(Date:12/2/2008)...hcare group at Frost & Sullivan,( http://www....t it will be,hosting an interactive analyst brief... on 11 December 2008 at 3pm GMT. , (Logo: ...O ) , With most diagnostic cardiology marke...are faced with an immense challenge of keeping pro...
Breaking Medicine News(10 mins):Health News:Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Will Diagnostic Cardiology Vendors Look to Product Innovation? 2
...in Andhra Pradesh have hit on a novel method of pr...n thousands of residents opened their// newspapers...three condoms on the front page. "Earlier we dist..., through milk vendors and at pan (tobacco) shops ...
...ticals, a leading player in the Indian drug indust...d and Drug Authority (FDA) for three// of its abbr...me. Orchid will be launching this product in the... partner, Apotex, the Chennai-based company said i...
...ts are high in saturated and trans fats, a high in...ed rate of decline in thinking, learning// and mem... essential for brain development and function, an ...ole in the development of brain plaques associated...
...British Medical Journal, researchers at Oxford Uni...er cent in the consumption of common foods// conta...increase in coronary heart disease. Trans fats ar...shelf life of food and is added to most fast foods...
Other Medicine News:Health News:High-Fat, Copper-Rich Diets Associated with Increased Rates of Cognitive Decline 2
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)
...es BchiVac V-500 with Vacuum Controller V-800 Ef... switching mechanism turns V-500 on and off as nee...ing Model V-500 is a powerful PTFE membrane vacu...s. Applications Ideally suited for use with up ...
...1000 is a new addition to the powerful PTFE membra...ce pump can achieve an ultimate vacuum of 1 mbar o... with vacuum drying ovens and centrifugal vacuum c...size up to industrial size rotary evaporators Bchi...
...500 is a powerful PTFE membrane vacuum pump design...ns Ideally suited for use with up to two rotary ...ents including vacuum ovens, concentrators, gel dr...es PEEK head resistant to chemicals and heat load...
Medicine Products: